Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Sales of Mounjaro and Zepbound missed estimates in Q3

The news: Eli Lilly reported weaker-than-expected sales in Q3 for its two GLP-1 blockbuster medications, Mounjaro and Zepbound.

  • For Q3 2024, worldwide Mounjaro revenues were $3.11 billion, while Zepbound brought in $1.26 billion in the US.
  • Analysts expected Mounjaro sales at $4.2 billion and $1.69 billion for Zepbound, according to LSEG data cited by Reuters.
  • Zepbound sales slightly decreased quarter over quarter, while sales for Mounjaro slightly increased.

You've read 0 of 2 free articles this month.

Create an account for uninterrupted access to select articles.
Create a Free Account